Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?

Background Pancreatic ductal adenocarcinoma (PDAC) requires complex multidisciplinary care. European evidence suggests potential benefit from regionalization, however, data characterizing the ideal setting in the United States are sparse. Our study compares the significance of four hospital designations on guideline-concordant care (GCC) and overall survival (OS). Patients and Methods The Texas Cancer Registry was queried for 17,071 patients with PDAC treated between 2004 and 2015. Clinical data were correlated with hospital designations: NCI designated (NCI), high volume (HV), safety net (SNH), and American College of Surgeons Commission on Cancer accredited (ACS). Univariable (UVA) and multivariable (MVA) logistic regression were used to assess associations with GCC [on the basis of National Comprehensive Cancer Network (NCCN) recommendations]. Cox regression analysis assessed survival. Results Only 43% of patients received GCC. NCI had the largest associated risk reduction (HR 0.61, CI 0.58–0.65), followed by HV (HR 0.87, CI 0.83–0.90) and ACS (HR 0.91, CI 0.87–0.95). GCC was associated with a survival benefit in the full (HR 0.75, CI 0.69–0.81) and resected cohort (HR 0.74, CI 0.68–0.80). NCI (OR 1.52, CI 1.37–1.70), HV (OR 1.14, CI 1.05–1.23), and SNH (OR 0.78, CI 0.68–0.91) all correlated with receipt of GCC. For resected patients, ACS (OR 0.63, CI 0.50–0.79) and SNH (OR 0.50, CI 0.33–0.75) correlate with GCC. Conclusions A total of 43% of patients received GCC. Treatment at NCI and HV correlated with improved GCC and survival. Including GCC as a metric in accreditation standards could impact survival for patients with PDAC.